MMP‐7 (matrilysin) expression in human brain tumors

Matrix metalloproteinases (MMP) which degrades protein components of the extra‐cellular matrix and basement membrane seems to be largely involved in cancer invasiveness. MMP proteolitic activity essentially comes from stromal cells but matrilysin (MMP‐7) is produced by the tumor itself. Thus, MMP‐7 is investigated to address the particular invasive behavior of human glioma. Both MMP‐7 mRNA and protein were clearly identified in human glioma. MMP‐7 mRNA expression was highly variable within our glioma population. When analyzing MMP‐7 mRNA expression in different primary brain tumors, we found highly variable levels of expression not related to their invasive behavior. In successive biopsies obtained in the same patients with glioblastoma, MMP‐7 mRNA was quantified and appeared variable, but intra‐individual variations were lower than inter‐individual differences. With a xenograft model of U87 human tumors in RAG2/γc immune‐deficient mice, the strict tumor origin of MMP‐7 was shown. Additionally, MMP‐7 expression by U87 cells which is low in culture was stimulated by these cells while forming tumors and the level of expression was higher when the tumor cells were implanted within the brain. These data provide some consistent information about cross‐talk occurring between the tumor and the surrounding stroma to regulate MMP‐7 expression. © 2007 Wiley‐Liss, Inc.

[1]  D. Fishman,et al.  Matrilysin (MMP‐7) promotes invasion of ovarian cancer cells by activation of progelatinase , 2005, International journal of cancer.

[2]  K. Sugimachi,et al.  Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  M. Brawer,et al.  Expression of metalloproteinase genes in human prostate cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[4]  V. Kähäri,et al.  Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets , 2002, International journal of cancer.

[5]  B. Fingleton,et al.  Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. , 2000, The Journal of clinical investigation.

[6]  K. Hirata,et al.  Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  V. Yong,et al.  Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. , 2003, Molecular cancer research : MCR.

[8]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[9]  Jack P. Witty,et al.  Expression and localization of matrix‐degrading metalloproteinases during colorectal tumorigenesis , 1994, Molecular carcinogenesis.

[10]  J. Furuyama,et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. , 1995, Journal of neurosurgery.

[11]  S. Shapiro,et al.  Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. , 1994, American journal of respiratory and critical care medicine.

[12]  C. Thorns,et al.  Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. , 2003, Anticancer research.

[13]  Y. Yamakawa,et al.  Expression of matrix metalloproteinases 2 and 7 in tumor cells correlates with the World Health Organization classification subtype and clinical stage of thymic epithelial tumors. , 2003, Human pathology.

[14]  I. Stamenkovic Matrix metalloproteinases in tumor invasion and metastasis. , 2000, Seminars in cancer biology.

[15]  Y. Nagashima,et al.  Expression of matrilysin in vascular endothelial cells adjacent to matrilysin‐producing tumors , 1997, International journal of cancer.

[16]  H. Peter,et al.  Copyright © American Society for Investigative Pathology Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Human Brain Tumors , 2022 .

[17]  S. Hauser,et al.  Stimulation of matrix metalloproteinase‐dependent migration of T cells by eicosanoids , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  L. Kappos,et al.  The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. , 2001, Brain : a journal of neurology.

[19]  D. Louis,et al.  Glioma classification: a molecular reappraisal. , 2001, The American journal of pathology.

[20]  Pascale Varlet,et al.  Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria , 1997, Journal of Neuro-Oncology.

[21]  T. Shiomi,et al.  MT1-MMP and MMP-7 in invasion and metastasis of human cancers , 2003, Cancer and Metastasis Reviews.

[22]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[23]  H. Larjava,et al.  Differential expression of matrilysin‐1 (MMP‐7), 92 kD gelatinase (MMP‐9), and metalloelastase (MMP‐12) in oral verrucous and squamous cell cancer , 2004, The Journal of pathology.

[24]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[25]  J. D. Di Santo,et al.  Dissecting NK cell development using a novel alymphoid mouse model: investigating the role of the c-abl proto-oncogene in murine NK cell differentiation. , 1999, Journal of immunology.

[26]  J. Tonn,et al.  Heterogeneous regional expression patterns of matrix metalloproteinases in human malignant gliomas , 1999, International Journal of Developmental Neuroscience.